Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study

NCT02548455 · View on ClinicalTrials.gov ↗

Study Summary

The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.

Conditions Studied

Interventions

  • DEVICE Quartet 1457Q LV Lead

Study Locations (20)

California

  • Scripps Health — La Jolla
  • Premier Cardiology, Inc. — Newport Beach
  • Stanford University Hospital — Stanford

Florida

  • Munroe Regional Medical Center — Ocala
  • Tallahassee Research Institute — Tallahassee

Georgia

  • Emory University Hospital — Atlanta
  • North Georgia Heart Foundation — Gainesville

Kentucky

  • Central Baptist Hospital — Lexington
  • One Health Cardiology — Owensboro

Massachusetts

  • Massachusetts General Hospital — Boston
  • Brigham and Women's Hospital — Boston

Alabama

  • Heart Center Research — Huntsville

Arizona

  • Arizona Arrhythmia Research Center — Phoenix

Arkansas

  • Cardiology Associates of Northeast Arkansas — Jonesboro

Trial Details

FieldValue
Enrollment Target 499 participants
Start Date 2015-10-27
Est. Completion 2017-03-21
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02548455

The ClinicalTrials.gov registry entry for NCT02548455 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which Quartet 1457Q LV Lead is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02548455 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02548455 about?

NCT02548455 is a clinical study titled "Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study". The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.

What is the current status of trial NCT02548455?

This trial is currently completed. It is a NA study. The enrollment target is 499 participants. The study started on 2015-10-27. Estimated completion is 2017-03-21.

What conditions does trial NCT02548455 study?

This clinical trial studies the following conditions: Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02548455?

The interventions under investigation include: Quartet 1457Q LV Lead (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02548455?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02548455 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial